Table 16.
Agents targeting TGF-β in preclinical or clinical studies
| Target | Molecular type | Agent | Company |
|---|---|---|---|
| TGFβRII | mAb | LY3022859 | Eli Lilly |
| TGFβRI/II | Receptor kinase inhibitor | LY2109761 | Eli Lilly |
| TGFβRI | Receptor kinase inhibitor | Vactosertib | MedPacto |
| Galunisertib | Eli Lilly | ||
| LY3200882 | Eli Lilly | ||
| LY573636 | Eli Lilly | ||
| SB-431542 | GlaxoSmithKline | ||
| SB-505124 | GlaxoSmithKline | ||
| IN-1130 | In2Gen | ||
| TGF-β and PD-L1 | BsAb | BiTP/YM101 | YZY Biopharma |
| TGFβRII and PD-L1 | Bifunctional fusion protein | TQB2858 | Chia-Tai Tianqing |
| M7824 | Merck KGaA | ||
| PM8001 | Pumis Biotechnology | ||
| SHR-1701 | Hengrui | ||
| TGFβRII and PD-1 | Bifunctional fusion protein | JS201 | Junshi |
| TGF-β and VEGF | BsAb | Y332 | YZY Biopharma |
| TGF-β | mAb | Fresolimumab | Genzyme |
| SRK181 | Scholar Rock | ||
| 1D11 | Genzyme | ||
| 2G7 | Genentech | ||
| Trap | AVID200 | Forbius | |
| Luspatercept | Acceleron | ||
| Antisense oligonucleotides | AP 12009 | Antisense Pharma | |
| AP 11014 | Antisense Pharma | ||
| Cancer vaccine | Vigil | Gradalis | |
| Lucanix | NovaRx | ||
| Integrin αvβ6 | mAb | 264RAD | AstraZeneca |
Note: BsAb bispecific antibody, mAb monoclonal antibody